ImmunoGen Inc.

3.83-0.0100-0.26%Vol 7.30M1Y Perf -40.00%
May 13th, 2022 16:00 DELAYED
BID3.80 ASK4.00
Open3.92 Previous Close3.84
Pre-Market3.92 After-Market-
 0.09 2.35%  - -
Target Price
9.43 
Analyst Rating
Moderate Buy 1.89
Potential %
146.21 
Finscreener Ranking
★★★★     53.47
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     47.11
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     50.53
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
8.58 
Earnings Rating
Strong Buy
Market Cap844.65M 
Earnings Date
6th May 2022
Alpha0.01 Standard Deviation0.21
Beta1.15 

Today's Price Range

3.784.00

52W Range

3.467.77

5 Year PE Ratio Range

-18.90-4.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-17.28%
1 Month
-28.41%
3 Months
-30.87%
6 Months
-33.04%
1 Year
-40.00%
3 Years
21.59%
5 Years
-6.59%
10 Years
-72.10%

TickerPriceChg.Chg.%
IMGN3.83-0.0100-0.26
AAPL147.114.55003.19
GOOG2 330.3167.09002.96
MSFT261.125.77002.26
XOM88.862.56002.97
WFC42.640.83001.99
JNJ176.85-1.0200-0.57
FB198.627.38003.86
GE75.051.77002.42
JPM119.091.05000.89
Financial StrengthValueIndustryS&P 500US Markets
4.90
5.00
0.04
0.06
-9.60
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
52.20
-180.60
-177.70
-138.40
-55.41
RevenueValueIndustryS&P 500US Markets
54.15M
0.25
21.97
5.34
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.21-0.1052.38
Q04 2021-0.18-0.175.56
Q03 2021-0.19-0.185.26
Q02 2021-0.18-0.1516.67
Q01 2021-0.19-0.1710.53
Q04 2020-0.040.16500.00
Q03 2020-0.20-0.1335.00
Q02 2020-0.18-0.1422.22
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.230.00-
9/2022 QR-0.26-8.33Negative
12/2022 FY-0.941.05Positive
12/2023 FY-0.74-10.45Negative
Next Report Date-
Estimated EPS Next Report-0.21
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume7.30M
Shares Outstanding220.54K
Shares Float219.77M
Trades Count26.11K
Dollar Volume27.92M
Avg. Volume4.36M
Avg. Weekly Volume5.97M
Avg. Monthly Volume3.26M
Avg. Quarterly Volume3.84M

ImmunoGen Inc. (NASDAQ: IMGN) stock closed at 3.83 per share at the end of the most recent trading day (a -0.26% change compared to the prior day closing price) with a volume of 7.30M shares and market capitalization of 844.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 75 people. ImmunoGen Inc. CEO is Mark J. Enyedy.

The one-year performance of ImmunoGen Inc. stock is -40%, while year-to-date (YTD) performance is -48.38%. IMGN stock has a five-year performance of -6.59%. Its 52-week range is between 3.46 and 7.77, which gives IMGN stock a 52-week price range ratio of 8.58%

ImmunoGen Inc. currently has a PE ratio of -6.90, a price-to-book (PB) ratio of 3.14, a price-to-sale (PS) ratio of 16.25, a price to cashflow ratio of 141.00, a PEG ratio of 2.32, a ROA of -32.54%, a ROC of -55.11% and a ROE of -68.12%. The company’s profit margin is -55.41%, its EBITDA margin is -177.70%, and its revenue ttm is $54.15 Million , which makes it $0.25 revenue per share.

Of the last four earnings reports from ImmunoGen Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. ImmunoGen Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ImmunoGen Inc. is Moderate Buy (1.89), with a target price of $9.43, which is +146.21% compared to the current price. The earnings rating for ImmunoGen Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ImmunoGen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ImmunoGen Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.38, ATR14 : 0.37, CCI20 : -132.67, Chaikin Money Flow : -0.19, MACD : -0.33, Money Flow Index : 32.76, ROC : -20.37, RSI : 32.46, STOCH (14,3) : 21.26, STOCH RSI : 0.43, UO : 37.36, Williams %R : -78.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ImmunoGen Inc. in the last 12-months were: Dean Jonathan Mitchell (Option Excercise at a value of $321 400)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (55.56 %)
5 (55.56 %)
5 (62.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (44.44 %)
4 (44.44 %)
3 (37.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.89
Moderate Buy
1.89
Moderate Buy
1.75

ImmunoGen Inc.

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

CEO: Mark J. Enyedy

Telephone: +1 781 895-0600

Address: 830 Winter Street, Waltham 02451, MA, US

Number of employees: 75

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

75%25%

Bearish Bullish

58%42%

TipRanks News for IMGN

Tue, 22 Mar 2022 12:05 GMT ImmunoGen (IMGN) Gets a Hold Rating from J.P. Morgan

- TipRanks. All rights reserved.

Mon, 21 Mar 2022 15:05 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (IMGN) and Decibel Therapeutics (DBTX)

- TipRanks. All rights reserved.

Tue, 01 Mar 2022 10:36 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: ImmunoGen (IMGN), uniQure (QURE) and Myovant Sciences (MYOV)

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 16:09 GMT ImmunoGen (IMGN) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits